Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)

In this review, we examine the current landscape of health resource utilization and cost-effectiveness data in the care of patient populations with immune thrombotic thrombocytopenic purpura. We focus on the therapeutic (therapeutic plasma exchange, glucocorticoids, rituximab, caplacizumab) and diagnostic (ADAMTS13 assay) health technologies employed in the care of patients with this rare disease. Health resource utilization and cost-effectiveness data are limited to the high-income country context. Measurement of TTP-specific utility weights in the high-income country context and collection of health resource utilization data in the low- and middle-income country settings would enable an evaluation of country-specific quality-adjusted life expectancy and cost-effectiveness of these therapeutic and diagnostic health technologies. This quantification of value is one way to mitigate cost concerns where they exist.

Automated summary

In this review, the utilization and cost-effectiveness data of health resources in the care of patients with immune thrombotic thrombocytopenic purpura were examined. The study focused on the therapeutic and diagnostic health technologies used for this rare disease, but the available data were limited to high-income countries. It is suggested that collecting health resource utilization data in low- and middle-income countries and measuring TTP-specific utility weights would enable a evaluation of the country-specific quality-adjusted life expectancy and cost-effectiveness of these health technologies.